ライフサイエンスコーパス: monthly

1 ly), weeks 7-20 (biweekly), and weeks 21-32 (monthly).

2 METHOD: Prescription data were obtained monthly.

3 Safety assessments were conducted monthly.

4 erapy: subcutaneous placebo injections BID + monthly 0.3 mg ranibizumab.

5 n therapy: subcutaneous AKB-9778 15 mg BID + monthly 0.3 mg ranibizumab; or (3) ranibizumab monothera

6 Mean ERMA over 18 months was 0.39+/-0.67 (monthly), 1.1+/-1.9 (TREX), and 0.49+/-1 mm(2) (control,

7 mg) colecalciferol (vitamin D3) followed by monthly 100 000 IU (2.5 mg) colecalciferol or equivalent

8 d in patients receiving the T&E (8.7) versus monthly (11.1) regimen, with mean number of postbaseline

9 (N=136 177) aged >/=66 years were calculated monthly, 24 months before and 12 months after generics c

10 and placebo at weeks 4 and 8), fremanezumab monthly (675 mg at baseline and 225 mg at weeks 4 and 8)

11 ocumab, 140 mg every 2 weeks and 420 mg once monthly, across quartiles of baseline PCSK9 levels.

12 t (95% CI, 0.01-0.03) per 10000 men for each monthly ad exposure over the entire period.

13 rgical candidates, and provides a convenient monthly administration schedule.

14 e have been concerns regarding its long-term monthly administration.

15 Monthly admission data for children under five years wit

16 that met the search criteria: 2 trials using monthly aflibercept and 2 using monthly ranibizumab, rep

17 In contrast, monthly aggregate changes across hospitals in hospital 3

18 s without opioid-positive urine test result [monthly and 4 times randomly] and self-report).

19 Vaginal microbiota were assessed monthly and categorized by Nugent score (0-3 = normal mi

20 At the inflection point between monthly and PRN dosing, when recurrence of edema is anti

21 he EP/NP pattern should be incorporated into monthly and seasonal outlooks that are of broad importan

22 HIV testing was done monthly and serum creatinine was assessed every 3 months

23 ssing glaucoma for 2 in-clinic (yearly and 6-monthly) and 3 home-monitoring (monthly, fortnightly, an

24 rns of bloom timing are similar in both low (monthly) and high (5 day) resolution data, although init

25 zumab quarterly, 4.6+/-0.3 with fremanezumab monthly, and 2.5+/-0.3 with placebo (P<0.001 for both co

26 fremanezumab quarterly, 379 to fremanezumab monthly, and 375 to placebo.

27 Angina frequency was categorized as none, monthly, and daily/weekly.

28 rkers every 4 weeks, bed spaces were sampled monthly, and screening swabs were obtained from patients

29 Thyroid function was assessed monthly, and the levothyroxine dose was adjusted to atta

30 he first 3 months and were slowly tapered to monthly, and then quarterly.

31 egating GEP to the longer timescales (daily, monthly, and yearly), however, environmental variation e

32 Monthly anti-VEGF injections were given until a dry macu

33 of a line to the graphical A&F plotting the monthly antibiotic prescribing rate of all dentists in t

34 15, 0.045, or 0.075 mg per kilogram) or once monthly (at a dose of 0.225, 0.45, 0.9, or 1.8 mg per ki

35 tly positive change in trend, ranging from a monthly average increase of 61 (95% CI 38-84) institutio

36 ational Climatic Data Center to estimate the monthly average temperature for each of these different

37 hod that determines these contributions from monthly-averaged data.

38 CARD curation is updated monthly based on an interplay of manual literature curat

39 Compared to current practices (seasonal/monthly based operation), integrated RTC strategies can

40 iral therapy, but should be followed up on a monthly basis for alanine aminotransferase followed by q

41 Patients were followed up on a 6-monthly basis for reassessment and further investigation

42 iling of AmAChE1 over a year-long cycle on a monthly basis revealed that AmAChE1 was predominantly ex

43 ow-dose tacrolimus monotherapy together with monthly belatacept applications.

44 nous crystalloid used in the unit alternated monthly between saline (0.9% sodium chloride) and balanc

45 f gadolinium-enhanced T1-weighted lesions on monthly brain MRI scans from weeks 8 to 24.

46 orrelation coefficients in hospitals' paired monthly changes in 30-day RARRs and 30-day RAMRs after d

47 s by utilizing annual climate projections of monthly changes in air temperature, precipitation, solar

48 expectedly, there was no correlation between monthly chlorophyll-a variability inside and outside the

49 trengthens the front during October-April in monthly climatology and about 87% of months from October

50 performance of weekly home monitoring over 6-monthly clinical testing was retained even when home mon

51 .5 years) was calculated using data from six monthly clinical visits.

52 ear-global, fine-grain ( approximately 1 km) monthly cloud frequencies from 15 y of twice-daily Moder

53 7) and GILA (10.1) cohorts compared with the Monthly cohort (13.1, P < 0.001).

54 Monthly cohort eyes received ranibizumab 0.3 mg every 4

55 62 toxic chemicals based on the simultaneous monthly collection of aerosol samples during 2015-2016 i

56 Average monthly color concentrations in Pockwock Lake and Lake M

57 Methods We studied the changes in mean monthly costs for a cohort of 24 patented, injectable an

58 reases over time, and the inflation-adjusted monthly costs rose since approval by 49% and 44%, respec

59 s maintenance program that includes at least monthly counseling with a trained interventionist.

60 g the 11 648 randomly assigned patients, the monthly cumulative incidence of MI was lower with contin

61 individuals to move through health states in monthly cycles from diagnosis until death.

62 I mortality by identifying studies reporting monthly data for ALRI mortality in the community and RSV

63 that the attack rate is unidentifiable with monthly data in Bahia.

64 sustained 6.6% (95% CI, 4.7%-8.4%; P < .001) monthly decrease in the rate of cultures per 100 patient

65 all vaccines except polio, with the trend of monthly decreases in the number of children vaccinated r

66 odel was initiated on Jan 1, 2016, producing monthly dengue forecasts until November, 2016.

67 s (CE) of monthly ZA, ZA every 3 months, and monthly denosumab in women with breast cancer and skelet

68 CE option and more reasonable alternative to monthly denosumab.

69 as more CE in reducing the risks of SRE than monthly denosumab.

70 ontrolled trial comparing daily TMP-SMX plus monthly dihydroartemisinin-piperaquine (DP) to daily TMP

71 osite adverse birth outcome was lower in the monthly dihydroartemisinin-piperaquine group (9.2%) than

72 to describe the safety and feasibility of a monthly distribution of ready-to-use therapeutic food (R

73 n 37-69 years old) received a median (range) monthly dose of 288 (230-336) mg MTX.

74 Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced mi

75 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or macular laser photocoagulation.

76 dose of 200000 IU, followed a month later by monthly doses of 100000 IU, or placebo for a median of 3

77 rcept injection (2 mg) every 8 weeks after 5 monthly doses with sham injections on nontreatment visit

78 monthly doses, then as needed), or 0.5-mg (3-monthly doses, then as needed) in RESTORE.

79 er, macular laser plus 0.5-mg ranibizumab (3-monthly doses, then as needed), or 0.5-mg (3-monthly dos

80 r visual and anatomic outcomes compared with monthly dosing at 1 year.

81 To compare monthly dosing with a treat and extend algorithm using r

82 d to further explore the cardiac safety with monthly dosing.

83 INTERPRETATION: Monthly DP appears well tolerated and effective for IPT.

84 Monthly DP appears well tolerated and effective for IPT.

85 During the intervention, monthly DP reduced malaria episodes by 55% overall (P <

86 oor residual spraying of insecticide, adding monthly DP to daily TMP-SMX did not reduce the risk of p

87 erved a nonsignificant increase in estimated monthly drinks in the first year after deployment that r

88 Differences in monthly drug cost between the experimental and control g

89 er surgery) and daily opioid dose (evaluated monthly during the year after surgery).

90 95% confidence interval (95% CI) 2.14-5.25], monthly earnings (OR 0.83, 95% CI, 0.77-0.89), supportin

91 ses were 30% higher, or 700 Euros more, than monthly earnings for full-time female nurses.

92 Unadjusted monthly earnings for full-time male nurses were 30% high

93 egression, the analysis estimated the log of monthly earnings for male and female nurses.

94 Potential monthly electricity generation from the conversion of gr

95 ray, compared with a placebo, did not reduce monthly epistaxis duration in the 3 consecutive months i

96 pling was found to underestimate the maximum monthly exposure to dissolved lead by 19%, while samplin

97 s, computerized feedback, text messages, and monthly face-to-face groups at the WIC clinics.

98 intervention to reduce albumin use involving monthly feedback and explicit financial incentives in th

99 Mothers used monthly feeding diaries to report the extent of breastfe

100 The treatment completion and monthly follow-up visit compliance rates were higher in

101 ifferences in rates of treatment completion, monthly follow-up visit compliance, transaminase elevati

102 aper presents the first detailed analysis of monthly food waste generation in California at a county

103 fetil, 1 g twice daily, and were followed up monthly for 6 months.

104 ab, at a dose of 70 mg or 140 mg, or placebo monthly for 6 months.

105 cal coherence tomography scans were acquired monthly for quantitative measures of the central retinal

106 y other week for two doses, or 300 or 500 mg monthly for two doses, with or without concurrent statin

107 yearly and 6-monthly) and 3 home-monitoring (monthly, fortnightly, and weekly) schedules, each runnin

108 mab-quarterly group, 41% in the fremanezumab-monthly group, and 18% in the placebo group (P<0.001 for

109 was -169.2 mum and -173.3 mum in the T&E and monthly groups, respectively.

110 Objective: To examine safety and effects of monthly high-dose IV pulse MTX in EF.

111 Monthly high-dose vitamin D supplementation does not pre

112 To examine whether monthly high-dose vitamin D supplementation prevents CVD

113 ents for maternal age, education, ethnicity, monthly household income, parity, infant BAZ at 12 mo of

114 formation time series to constrain models of monthly hydrospheric loading and the resulting stress ch

115 ns aged 70 years or older who were evaluated monthly in 13 functional activities (1998-2012).

116 Drugs were administered monthly in each of the groups for a total duration of 24

117 (household vouchers that need to be redeemed monthly in order).

118 uring 1984-1987), each with weights measured monthly in the first year.

119 The 3-month intervention consisted of a $60 monthly incentive in a virtual account, from which $2 wa

120 ates of MI with continued thienopyridine (MI monthly incidence 0.16% versus 0.51%, P<0.001, for score

121 rial meningitis global database by compiling monthly incidence data as reported by country-level surv

122 eneralised additive mixed model to model the monthly incidence of physical assaults as a function of

123 advertisement exposure was associated with a monthly increase in rates of new testosterone testing (r

124 The NNSS for the 14 participants treated monthly increased at a rate of 1.22, SEM 0.34 points per

125 data were available, ASCO benefit score and monthly incremental drug costs were negatively correlate

126 pectively, while the average increase in the monthly influenza cases was 14.6% (95% CI, 9.0%-21.0%),

127 results showed that the expected decrease in monthly influenza cases was 19.3% (95% credible interval

128 SS) >60) individuals with schizophrenia to 3 monthly infusions of 8 mg/kg tocilizumab or placebo (nor

129 ally assigned in cohorts of three to receive monthly initial intrathecal HPbetaCD at doses of 50, 200

130 nded-release naltrexone, a sustained-release monthly injectable formulation of the full mu-opioid rec

131 assessing expected response at month 6 after monthly injection of anti-VEGF agents for treating ME du

132 ns), 36 received subcutaneous immunotherapy (monthly injections containing 20 microg of Phleum p 5 an

133 Study eyes received 4 monthly injections followed by pro re nata injections un

134 nge of the DRIL extent following the first 3 monthly injections identifies eyes with a high likelihoo

135 Eyes in the TREX and GILA cohorts received 4 monthly injections of ranibizumab 0.3 mg followed by a t

136 Monthly injections were offered until no signs of diseas

137 After initial 3 monthly injections, patients in the ranibizumab with or

138 Monthly international conference calls were held from 20

139 nd control (advice only), both provided at 6-monthly intervals during a 3-y follow-up.

140 evention advice) or advice-only control at 6-monthly intervals.

141 rol (100 mug keyhole limpet haemocyanin) via monthly intradermal injection until progression or intol

142 XR-NTX was monthly intramuscular injections (Vivitrol; Alkermes) an

143 l, dose-escalation phase 1-2a study, we gave monthly intrathecal HPbetaCD to participants with NPC1 w

144 f aflibercept (monotherapy arm), followed by monthly intravitreal aflibercept injections in both arms

145 Treatment-naive RVO-ME receiving monthly intravitreal bevacizumab.

146 Monthly IPT-DP was associated with an 84% reduction in t

147 Monthly IPT-DP was associated with fewer serious adverse

148 Monthly maximum wind speed was predictive of monthly litterfall, yet the influence of precipitation a

149 Both groups received 3 monthly loading doses and were then treated every 8 week

150 2.0 mg monthly or pro re nata (PRN) after 3 monthly loading doses.

151 was the lowest during monotherapy with once-monthly long-acting injectable paliperidone (hazard rati

152 Study eyes received 6 monthly mandatory injections followed by as-needed injec

153 Monthly maximum wind speed was predictive of monthly lit

154 y and linearly associated with country-level monthly mean (prevalence ratio = 1.31 [95% confidence in

155 For these we produced monthly mean density maps.

156 are controlled by OS emissions; > 50% of the monthly mean HNCO arose from the OS.

157 For all users, there was a monthly mean rate of 100 adverse events for 1000 angiote

158 .92 [0.71-1.18] per kJ/m(2) for center-level monthly mean UVR for the 13- to 14- and 6- to 7-year-old

159 24 [0.96-1.59] per kJ/m(2) for country-level monthly mean UVR).

160 uct and completed at least one post-baseline monthly measurement.

161 In this study, four time series of monthly meteorological, hydrological, soil moisture, and

162 The mean change in monthly migraine days at week 12 was -3.4 (SE 0.4) days

163 The primary endpoint was the change in monthly migraine days from baseline to the last 4 weeks

164 Erenumab 70 mg and 140 mg reduced monthly migraine days versus placebo (both doses -6.6 da

165 numab 70 mg and 140 mg reduced the number of monthly migraine days with a safety profile similar to p

166 The mean reductions in monthly migraine days with the 7 mg (-2.2 [SE 0.4]) and

167 relationships between seasonal influenza and monthly minimum temperature (MIT), monthly vapor pressur

168 I, 1.5%-15.0%) for a 1 degrees C increase in monthly MIT at <15, 15-64, and >/=65 years of age, respe

169 r, ranibizumab 0.5 mg was dosed as needed if monthly monitoring indicated a loss of VA resulting from

170 PRN treatment with monthly monitoring was effective in maintaining early vi

171 sts: US$3445 (annual monitoring) to US$5393 (monthly monitoring) per patient, respectively (standard

172 direct observation, self-administration with monthly monitoring, or self-administration with weekly t

173 ation with weekly text message reminders and monthly monitoring.

174 The median reduction in monthly motor seizures was 36.5% (IQR 0-64.7).

175 nalysis cohort included 88 eyes in 3 groups: monthly (n = 19), TREX (n = 30), and control fellow eyes

176 116 subjects were randomized into 3 cohorts: Monthly (n = 30), TReat and EXtend without macular laser

177 either a ranibizumab 0.5 mg T&E (n = 323) or monthly (n = 327) regimen.

178 Monthly Nielsen ratings for testosterone DTCA in the 75

179 ustralian Paediatric Surveillance Unit, with monthly notification of new cases of acute FPIES in infa

180 ing hospitals (n = 135; 3% of all CDIs); the monthly number was constant over time.

181 by the typically coarse temporal resolution (monthly) of global climate models.

182 Overall, 89.8% (T&E) and 90.2% (monthly) of patients completed the study.

183 Data were measured monthly on a rolling 12-month mean basis.

184 as either an IV infusion (10-40 mg/kg) given monthly or bimonthly, or as an SC injection (5 mg/kg) ev

185 y developed for parenteral administration at monthly or longer intervals.

186 f 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with

187 in eyes with neovascular AMD, whether dosed monthly or per TREX regimen.

188 Intravitreal ranibizumab 0.5 mg or 2.0 mg monthly or pro re nata (PRN) after 3 monthly loading dos

189 e neovascular AMD in 1 eye randomized 1:2 to monthly or TREX ranibizumab.

190 ophy (ERMA) in eyes treated with ranibizumab monthly or using a treat-and-extend (TREX) regimen for n

191 95% confidence interval (CI): 1.37, 4.23) or monthly (OR = 1.94, 95% CI: 1.17, 3.24) versus once to a

192 cumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections.

193 eceive subcutaneous romosozumab (210 mg once monthly) or subcutaneous teriparatide (20 mug once daily

194 ts received evolocumab 420 mg subcutaneously monthly, or if on apheresis every 2 weeks.

195 SDCS (weekly: OR = 0.64, 95% CI: 0.47, 0.85; monthly: OR = 0.60, 95% CI: 0.44, 0.81; yearly: OR = 0.5

196 Monthly outdoor air concentrations ranged from 9.2 to 19

197 supplementation of 100 000 IU colecalciferol monthly over 2.5-4.2 years did not prevent falls or frac

198 at baseline treated with ranibizumab 0.5 mg monthly (PED present at baseline, +9.0 letters; PED abse

199 g 15 microg of major allergen Phleum p 5 and monthly placebo injections), 36 received subcutaneous im

200 Use of monthly PPT for 1 year reduced colonization with several

201 nes and training on appropriate prescribing, monthly prescribing peer-review meetings, and brief care

202 mg PRN (present, +8.4; absent, +7.9), 2.0 mg monthly (present, +7.1; absent, +11.1), or 2.0 mg PRN (p

203 monthly temperature and post-earthquake mean monthly pressure were negatively associated with ZIKV in

204 eduction of the treatment burden compared to monthly PRN.

205 Median monthly provider volumes were 79 (interquartile range [I

206 unar vertical migration (LVM) may facilitate monthly pulses of carbon remineralization, as they occur

207 ely 50% and 70% after 3 years of annual or 3-monthly (quarterly) exposures to ivermectin.

208 opagate into estimates of temporal trends in monthly rainfall and descriptive hydroclimate indices.

209 s a high chance of exceeding observed record monthly rainfall totals in many parts of the UK.

210 high chance of exceeding the observed record monthly rainfall totals in many regions of the UK.

211 ithout laser received a minimum of 3 initial monthly ranibizumab injections until visual acuity (VA)

212 trials using monthly aflibercept and 2 using monthly ranibizumab, representing 1328 patients.

213 The monthly rate of blood culture contamination for all nurs

214 The numerically greatest monthly rate of SCD was in the 31- to 90-day time period

215 ctionality was higher if fees were collected monthly rather than in response to system breakdown.

216 linical follow-up and therapeutic foods on a monthly rather than weekly basis, may be one alternative

217 outpatient treatment of SAM were provided a monthly ration of RUTF.

218 noninferior and clinically comparable with a monthly regimen in improving VA from baseline to the end

219 The monthly regimen induced a dose-dependent mean maximum an

220 inferiority of ranibizumab 0.5 mg T&E versus monthly regimen, as assessed by the change in best-corre

221 E regimen was noninferior (P < 0.001) to the monthly regimen, with a least squares mean BCVA change f

222 bizumab 0.5 mg treat-and-extend (T&E) versus monthly regimens in patients with neovascular age-relate

223 rs was restricted to community posters and 6-monthly reminders during routine community meetings.

224 It is demonstrated here that the use of monthly representations of AOD leads to systematic under

225 rough samplers simultaneously sampled air at monthly resolution.

226 The monthly risk of SCD shortly after CABG among patients wi

227 lation to target doses (200-600 mg) and then monthly rituximab commenced (375 mg/m(2) in month 1 and

228 ade reservoirs and human water use) affected monthly river water availability and water scarcity over

229 We collected cumulative monthly samples during the pesticide application seasons

230 ter (RHRW) tanks repeatedly sampled over six monthly sampling events (n = 144) from August 2015 to Ma

231 was maintained over 4 wk of follow-up with a monthly schedule of RUTF distribution.

232 the intervention group received standardized monthly scorecards showing the median surgical supply di

233 Progress was assessed by monthly sensory and motor function tests during routine

234 We examined monthly service use data for eight maternal and child he

235 e sex workers in Mombasa, Kenya, completed a monthly sexual behavior interview and clinical examinati

236 taneous AKB-9778 15 mg twice per day (BID) + monthly sham intraocular injections; (2) combination the

237 Individuals assigned randomly to monthly sham, 0.3-mg ranibizumab, or 0.5-mg ranibizumab

238 vents than placebo, daily co-trimoxazole, or monthly SP.

239 a competition between the orbitally enforced monthly stability and the fluctuations/noise induced by

240 that the spatio-temporal distribution of the monthly stability and the magnitude of the noise reveal

241 /day EPA + 500 mg/day DHA) for 90 days, with monthly study visits.

242 Once-monthly subcutaneous administration of fitusiran resulte

243 800 mg/g to TGF-beta1 mAb (2-, 10-, or 50-mg monthly subcutaneous dosing for 12 months) or placebo.

244 Mice received monthly subcutaneous infusions of cytokines while also b

245 and randomly assigned in a 3:2:2:2 ratio to monthly subcutaneous placebo, AMG 334 7 mg, AMG 334 21 m

246 omly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral

247 Although monthly supplementary immunization activities (SIAs) con

248 ted for a significantly higher proportion of monthly supplies by volume, and therefore, also by total

249 , both were delivered through workbooks with monthly support visits.

250 locumab 140 mg every 2 weeks and 420 mg once monthly suppressed circulating PCSK9 levels by 90% to 10

251 Here we systematically scan monthly surface temperature indices and spatial datasets

252 and followed to 24 months with collection of monthly surveillance and diarrheal stools.

253 ce with supplementation was 87%, assessed by monthly tablet counts.

254 rehensive unit-based safety programs through monthly teleconferences.

255 Pre-earthquake mean maximum monthly temperature and post-earthquake mean monthly pre

256 Monthly temperature fluctuations inside and outside the

257 was significantly associated with increased monthly temperature range when compared with the month b

258 We show that monthly temperature variability and autocorrelation incr

259 e variability appears to influence trends in monthly temperature variability and autocorrelation.

260 ES is associated with an increase in monthly temperature variation.

261 field loss was achieved after 2.5 years of 6-monthly testing in the clinic, weekly home monitoring ac

262 Monthly testosterone advertising ratings were linked to

263 aterials, a Neighborhood Resource Guide, and monthly text messages) or (2) enhanced primary care plus

264 ls) was measured biweekly until 12 weeks and monthly thereafter.

265 ns of cytokines while also being assessed at monthly time points using an extensive range of behavior

266 source of estuarine variability by comparing monthly time series of temperature and chlorophyll-a ins

267 ained progressively less GEP variability: At monthly timescales, it explained only 3%, much less than

268 d with edema recurrence upon transition from monthly to pro re nata (PRN) dosing were correlated in A

269 Study monitoring was monthly to the primary endpoint at month 12 and then pro

270 ed as duplicate studies and 524, for lack of monthly treatment data for 2 years, leaving 4 studies fo

271 ients can be monitored directly during their monthly treatment visits.

272 After two monthly treatments with goserelin and exemestane, a sens

273 The monthly trend of adverse events was affected for generic

274 ficient was calculated for hospitals' paired monthly trends in 30-day RARRs and 30-day RAMRs after di

275 Monthly trends in each hospital's 30-day RARRs and 30-da

276 rrelates monthly trends in unemployment with monthly trends in reported spontaneous abortion, lagged

277 ish registries by Bruckner et al. correlates monthly trends in unemployment with monthly trends in re

278 oved by 123 mum, 146 mum, and 166 mum in the Monthly, TREX, and GILA cohorts, respectively (P = 0.47)

279 improved by 8.6, 9.6, and 9.5 letters in the Monthly, TREX, and GILA cohorts, respectively (P = 0.8).

280 e assessed 2 weeks after randomisation, then monthly until week 20 or occurrence of wound closure.

281 urgery and at 1 day, 1 week, 1 month, then 3-monthly up to 1 year, then half-yearly up to 3 years pos

282 achieved), or loss incentive ($42 allocated monthly upfront and $1.40 removed each day the goal was

283 Mentee hospitals reported data monthly using a standardized template.

284 m, minimum, standard deviation, and range of monthly UV dose exposures were assessed using linear mix

285 Mean monthly values of mean adequacy ratio, energy density, a

286 uenza and monthly minimum temperature (MIT), monthly vapor pressure, school calendar pattern, and Ind

287 (13.3, 37.3 nmol/L)] and showed significant monthly variation (P < 0.0001) with the highest values i

288 es and self-reported dietary intakes at each monthly visit (0.5-4.5 mo).

289 termined their parasitological status during monthly visits and incidental clinical episodes.

290 e visit in the third trimester of pregnancy, monthly visits to children younger than 2 years to suppo

291 f achieved protective drug levels during the monthly visits, but adherence decreased with quarterly v

292 The BCVA was measured at monthly visits.

293 This result does not support the use of monthly vitamin D supplementation for this purpose.

294 Ranibizumab monthly was best able to resolve each type of fluid.

295 locumab 140 mg every 2 weeks and 420 mg once monthly were associated with significant reductions in L

296 se clinical trial of ivermectin, comparing 3-monthly with annual treatments administered for 3 years

297 The monthly within-drug class market share of prescriptions

298 , hygiene, care, and stimulation, as well as monthly women's group meetings to promote individual and

299 acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of SREs.

300 to determine the cost-effectiveness (CE) of monthly ZA, ZA every 3 months, and monthly denosumab in